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The aim of the present study was to predict the prognosis of Chronic obstructive pulmonary
disease (COPD) patients who underwent comprehensive pulmonary rehabilitation (PR). A
total of 144 patients who performed PR between 1992 and 1999 was assessed. After PR, 67
patients underwent lung volume reduction surgery (LVRS). Baseline data before PR
consisted of body mass index, serum albumin levels, use of supplement oxygen at home,
pulmonary function, arterial blood gas analysis, and distance and fall of hemoglobin
oxygen saturation (DSpO2) in 6-min walk test. In addition to pre-PR factors, treatment with
LVRS was taken into the analysis. The prognostic significance of variables influencing
survival was determined by univariate analysis with Log rank test or multivariate analysis
using Cox’s proportional hazard model. By a median follow-up time of 8.4 years, the
median survival time was 8.1 years (95% confidence interval: 6.9–9.4 years). Albumin
level, PaCO2, distance and DSpO2 were significant prognostic factors in univariate analysis.
LVRS did not affect the prognosis. The multivariate analysis showed short distance and
increase of DSpO2 as significant independent predictors of the risk of death. 6-min walk
test was very useful for predicting the prognosis of the COPD patients.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
of Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700 8558, Japan.
226.
ama-u.ac.jp (N. Takigawa).
ARTICLE IN PRESS
N. Takigawa et al.562Introduction
Chronic obstructive pulmonary disease (COPD) has become a
common disease worldwide.1 The prevalence of COPD in
subjects aged X40 years increased 10.9% more than
expected according to a Japanese epidemiology study
conducted in 2000.2 COPD is currently the fourth leading
cause of death in the world, and further increases in the
prevalence and mortality of the disease can be predicted in
the coming decades.3 Several factors including reduced
expiratory volume in 1 s (FEV1), hypoxia, hypercapnea, a
short distance walked in a fixed time, a high degree of
functional breathlessness, and a low body mass index (BMI)
were associated with an increased risk of death.3,4
Pulmonary rehabilitation (PR) is an effective intervention
in patients with COPD.1,5 Troosters et al. reported that the
current best estimate using 7 randomized studies (total 596
patients) was that PR reduced the short-term (1–1.5 year)
risk of dying by 31% although this reduction was not
statistically significant.6 In addition, lung volume reduction
surgery (LVRS) has been proposed as a palliative treatment
for severe COPD patients.3 Overall, LVRS offered no survival
benefit; however, their subgroup analysis demonstrated that
patients with predominantly upper-lobe emphysema and
low base-line exercise capacity had an advantage in
survival.7 Accordingly, PR and LVRS may prolong survival
for COPD patients.
We started our comprehensive PR program for COPD in
1992 at Minami-Okayama Medical Center and LVRS was
performed in eligible patients after PR. The aim of this study
was to predict the prognosis of COPD by evaluating
prognostic factors in all patients participating in our PR
program despite LVRS.Methods
The diagnosis of COPD and classification of severity was
defined according to the global strategy for the diagnosis,
management, and prevention of COPD updated 2004.3 The
patients have symptoms of cough, sputum, or dyspnea, and/
or a history of exposure to risk factors for the disease. The
presence of a postbronchodilator FEV1o80% of the pre-
dicted value in combination with an FEV1/forced vital
capacity (FVC)o70% confirms the presence of airflow
limitation that is not fully reversible. Reversibility was
defined as an increase in FEV1 greater than 12% and/or
200mL after inhalation of b-agonist. Classification of
severity was as follows: mild COPD (stage I), FEV1480%
predicted; moderate COPD (stage II), 50% pFEV1o80%;
severe COPD (stage III), 30%pFEV1o50%; very severe COPD
(stage IV), FEV1o30%.3 Inclusion criteria of this study were
as follows: (1) the ability to walk for 6min, (2) never having
participated in a rehabilitation program before, (3) absence
of a comorbid disease that would make it unlikely that the
patient could participate in a PR program, for example,
severe pulmonary hypertension with dizziness or syncope on
exercise, severe congestive heart failure refractory to
medical management, unstable coronary disease, and
mental deterioration. The patients received optimal med-
ical treatment including b-agonists, anticholinergic drugs,
theophylline, and/or (inhaled or oral) steroids. A stablecondition whilst receiving medical treatment was required
before PR commenced. This study was performed as part of
our standard inpatient treatment and care.
Baseline data before PR consists of height, body weight,
BMI, serum albumin level, and use of supplement oxygen at
home. Pulmonary function data such as FEV1% predicted,
FEV1/FVC, and % vital capacity (VC) were assessed with
spirometry (Chestac-25, Chest, Tokyo, Japan). Predicted
FEV1 values were obtained from the guidelines of the
Japanese Respitratory Society8: FEV1 (L) for men ¼
0.036 height (cm)0.028 age (yr)1.178; FEV1 (L) for
women ¼ 0.022 height (cm)0.022 age (yr)0.055. Ar-
terial blood gases were taken at rest. Patients with
hypoxemia at rest (o55 Torr) were prescribed oxygen
therapy, so that PaO2 and PaCO2 were measured while they
were receiving oxygen. The patients performed 6-min walk
(6MW) tests. Six-min walk distance (6MWD) was defined as
the longest distance possible in 6MW without encourage-
ment. A practice walk was not included. They were allowed
to stop and rest if necessary. They walked with hemoglobin
oxygen saturation (SpO2) monitors. DSpO2 (SpO2 level just
before 6MWminimum SpO2 level during 6MW) was also
assessed. All the data were before PR.
The comprehensive PR including exercise and educational
activities, which are described elsewhere in detail,9 were
performed using a hospitalized program from 4 to 8 weeks.
Briefly, patients attended the rehabilitation unit on 5 half-
days per week. Exercise included cycle ergometer training,
treadmill training, upper and lower extremity strength
training, breathing therapies, and relaxation therapies.
The education program was also given on weekdays.
Inclusion criteria for LVRS were as follows: (1) marked
restriction in the activity of daily life despite maximal
medical therapy; (2) marked hyperinflation (% total lung
capacity4120%) by dilutional method; (3) diffuse but
inhomogeneous emphysema (existence of target areas); (4)
ability to participate in a vigorous PR program before and
after LVRS; (5) smoking cessation for at least 3 months.
Exclusion criteria for LVRS were as follows: (1) pulmonary
hypertension (mean pulmonary artery pressure430mmHg)
measured by Swan-Ganz catheter; (2) active bronchopul-
monary infection; (3) severe bronchial asthma; (4) severe
pleural adhesion (for example, prior thoracotomy or
chemical pleurodesis); (5) hypercapnea (PaCO2460 Torr).
10
The patients underwent PR for 4 weeks after LVRS.
Statistical analyses were performed with the SPSS Base
SystemTM and Advanced StatisticsTM programs (SPSS, Chica-
go, IL, USA). To compare categorized variables between two
groups, Pearson w2 was used. The influence of variables on
survival was studied by univariate and multivariate analyses.
We categorized potential prognostic variables, which were
dichotomized into normal and abnormal values based on
standard norms (PaCO2: 45 Torr, %VC: 80%); the usual
baseline of the supplemental oxygen for hypoxemic patients
(PaO2: 60 Torr); the cutoff line in stage III and IV (FEV1% of
predicted: 30%), or median values for age, BMI, albumin,
6MWD and DSpO2 in this study. All survival data have been
updated to 13 December 2004. The overall survival time
from the beginning of PR was calculated using the method of
Kaplan-Meier. We determined the prognostic significance of
variables by univariate analysis with Log rank test or
multivariate analysis using Cox’s proportional hazard model
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Table 1 Univariate analysis by Log rank test.
Variable n MST, year (95% CI) P
Age (year)
o67 65 8.1 (n.d.) 0.59
X67 79 7.0 (5.2–8.8)
Prognostic factors in COPD 563in a stepwise backward fashion. The variables incorporated
into the multivariate analysis are those that were Po0.3 in the
univariate analysis. In addition to pretreatment factors, the
LVRS was taken into the variables because LVRS might affect
survival. Pearson’s correlation coefficient (r) was used to
examine the degree of association of 6MWD and DSpO2. For all
comparisons, Po0.05 was considered statistically significant.Sex
Men 132 7.6 (5.8–9.4) 0.089
Women 12 8.3 (n.d.)
Body-mass index
o18 kg/m2 68 8.1 (n.d.) 0.89
X18 kg/m2 76 7.6 (5.6–9.7)
Albumin
o3.9 g/dL 65 5.6 (3.6–7.6) 0.015
X3.9 g/dL 79 Not reached
6MWD
o340m 70 5.8 (3.0–8.6) 0.024
X340m 74 8.1 (n.d.)
DSpO2
o6% 65 11.4 (n.d.) 0.0033
X6% 79 5.8 (3.9–7.7)
PaCO2
o45 Torr 84 Not reached 0.012
X45 Torr 60 6.8 (4.2–9.4)
PaO2
o60 Torr 30 8.1 (n.d.) 0.60
X60 Torr 114 7.6 (6.1–9.1)
%VC
o80% 98 7.6 (5.8–9.5) 0.62
X80% 46 8.1 (n.d.)
FEV1, % predicted
o30% 88 7.6 (5.7–9.6) 0.10
X30% 56 Not reached
LVRS
Yes 67 7.6 (6.6–8.9) 0.59
No 77 11.4 (n.d.)
HOT
Yes 75 8.3 (3.7–13.0) 0.24
No 69 7.6 (6.1–9.1)
MST: median survival time; CI: confidence interval; LVRS: lung
volume reduction surgery; HOT: home oxygen therapy; n.d.
not determined.Results
Between 13 July 1992 and 10 December 1999, 132 men and
12 women participating in our PR program were assessed for
this study. Of the 144 patients in this study, 9 were classified
as having stage II COPD, 47 stage III, and 88 stage IV. The
median age was 67 years and range of 45–79 years. The
median BMI was 18 kg/m2 (range: 12.4–28.4 kg/m2); albumin
level: 3.9 g/dL (range: 2.6–4.6 g/dL); 6MWD: 340m (range:
60–510m); DSpO2: 6% (range: 0–33%); FEV1% predicted:
26.9% (range: 11.9–71.9%); FEV1/FVC: 40.1% (range:
22.7–66.9%); %VC: 69.0% (range: 26–129%); PaO2: 68.2 Torr
(range: 45.7–100 Torr); PaCO2: 43.7 Torr (range: 28.8–
93.8 Torr). When clinical stage was categorized in two
groups of patients based on FEV1% of predicted (o30% vs.
X30%), the median values were 46.4 Torr vs. 40.0 Torr in
PaCO2; 67.7 Torr vs. 69.5 Torr in PaO2; 60.5% vs 85.2% in %VC;
22.6% vs. 35.0% in FEV1% of predicted, respectively. There
were 127 patients who had smoked and 17 who had never
smoked. 75 patients received home oxygen therapy at the
time of PR and 67 underwent LVRS after PR. At the time of
analysis, 55 patients were dead, 89 were alive. Cause of
death was as follows: cardiopulmonary insufficiency: 48
(cause of cardiopulmonary insufficiency: myocardial infarc-
tion 2, bacterial pneumonia 1, congestive heart failure 2,
not specified cause 43); lung cancer: 4; stomach cancer: 1;
rupture of abdominal aortic aneurysm: 1; bleeding of
duodenal ulcer: 1. By a median follow-up time of 8.4 years,
the median survival time was 8.1 years (95% confidence
interval [CI]: 6.9–9.4 years).
Univariate survival analysis showed that the following
characteristics were highly significant prognostic factors
favoring longer survival (with associated P valueo0.05):
6MWD (X340m), DSpO2 (o6%), PaCO2 (o45Torr), and
albumin level (X3.9 g/dL) (Table 1) (Fig. 1a–d). Other
variables that may be discriminant for survival (with
associated P values between 0.05 and 0.3) were FEV1%
predicted (Fig. 1e), sex (Fig. 1f), and home oxygen therapy.
LVRS did not discriminate for survival (P ¼ 0.59) (Fig. 1g).
Comparison of characteristics with or without LVRS was shown
in Table 2. The younger patients underwent LVRS (P ¼ 0.003)
and those with higher albumin level received LVRS
(P ¼ 0.078), which might be associated with being favorable
for longer survival. On the other hand, the patients with lower
FEV1% predicted (P ¼ 0.000), those with higher PaCO2 level
(P ¼ 0.016) and those with higher DSpO2 level (P ¼ 0.078)
underwent LVRS, which might be unfavorable for survival.
Using multivariate analysis, patients were analyzed to
determine factors affecting their prognosis. The variables
incorporated into this analysis are sex, serum albumin level,
use of supplement oxygen at home, 6MWD, DSpO2, PaCO2,
FEV1% predicted, and LVRS. Independently significant factors
influencing survival were 6MWD (P ¼ 0.005) and DSpO2(P ¼ 0.004) (Table 3). There was no correlation between
6MWD and DSpO2 (r ¼ 0.028, P ¼ 0.744). When all patients
were categorized into 2 using 6MWD and DSpO2, 105 patients
with 6MWD X340m and/or DSpO2o6% had better prognosis
(median survival time: 11.4 year; 95% CI: not determined,
mean survival time: 8.4 years, 95% CI: 7.5–9.3 years); 39
patients with 6MWDo340m and DSpO2X6% had worse
prognosis (median survival time: 4.0 years; 95% CI: 2.7–5.3
years, mean survival time: 4.5 years, 95% CI: 3.6–5.4 years).
There was a significant difference between the 2 categor-
ized patients (P ¼ 0.000) (Fig. 2).Discussion
Predictors of mortality from COPD include FEV1, BMI,
respiratory symptoms, exercise capacity, PaO2, PaCO2,
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Figure 1 Survival curves according to the 6MWD (a), DSpO2 (b), PaCO2 (c), albumin level (d), FEV1% predicted (e), sex (f), and LVRS
(g).
N. Takigawa et al.564exacerbations, and their combinations.3 Among them, the
combination index using BMI, FEV1, dyspnea scale and 6MWD
was a more powerful indicator than the previously reported
prognostic factors in predicting the risk of death.4 However,
treatment such as PR or LVRS was not described there. The
patients with FEV1o80% were recommended to perform
PR.3 There have been three indications of survival benefits
by PR.11–14 Ries et al.11 reported that survival rates were61% in PR group and 56% in control group after 6 years of
follow-up, and the difference was a slight but not significant
(P ¼ 0.32). Griffiths et al.12 found that six of 99 patients
(6%) in PR group and 12 of 101 (12%) in control group died
during 1-year of follow-up. A tendency for greater survival in
patients who underwent PR after hospitalization for an
acute exacerbation of COPD was also reported.14 However,
these were insufficient to demonstrate improved survival
ARTICLE IN PRESS
Table 2 Comparison of characteristics with or without
LVRS.
LVRS
 + Total P
Age, year
o67 26 39 65 0.003
X67 51 28 79
Sex
Men 69 63 132 0.34
Women 8 4 12
Body mass index
o18 kg/m2 38 30 68 0.58
X18 kg/m2 39 37 76
Albumin
o3.9 g/dL 40 25 65 0.078
X3.9 g/dL 37 42 79
6MWD
o340m 36 34 70 0.63
X340m 41 33 74
DSpO2
o6% 40 25 65 0.078
X6% 37 42 79
PaCO2
o45 Torr 52 32 84 0.016
X45 Torr 25 35 60
PaO2
o60 Torr 16 14 30 0.99
X60 Torr 61 53 114
%VC
o80% 52 46 98 0.89
X80% 25 21 46
FEV1, % predicted
o30% 35 53 88 0.00
X30% 42 14 56
Pearson w2 test was used for comparison between two groups.
LVRS: lung volume reduction surgery.
Table 3 Multivariate analysis by Cox proportional
hazard model.
Exp (b) 95% CI P
Sex 0.320 0.076–1.354 0.122
Albumin 0.588 0.338–1.023 0.060
6MWD 0.447 0.256–0.779 0.005
DSpO2 2.393 1.317–4.346 0.004
Poor
Good
Years
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al
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Figure 2 When all patients were categorized into two groups
using 6MWD and DSpO2, patients with 6MWDX340m and/or
DSpO2o6% had good prognosis and patients with 6MWDo340m
and DSpO2X6% had poor prognosis.
Prognostic factors in COPD 565after PR. Troosters et al.6 also reported that PR might
prolong survival as a result of analysis using 7 randomized
studies. In addition, LVRS for patients with predominantly
upper-lobe emphysema and low base-line exercise capacity
had produced survival benefits.7 Accordingly, we planned to
evaluate prognostic factors in COPD patients participating in
our PR programs and take LVRS into consideration in this
analysis.Our multivariate analysis showed that only distance and
oxygen desaturation in 6MW test were independent prog-
nostic factors. 12MWD was reported to be a significant
prognostic factor.15 We cannot tell which (6MWD or 12MWD)
is better for predicting prognosis. The mean FEV1% predicted
(38719%) in their study15 was much higher than that
(29.2711.3%) in our study. Actually, some patients in our
study could not walk for 12min. In the severe COPD patients
at least, 6MWD seems more useful than 12MWD. There have
been a few studies on exercise-induced hypoxemia as a
prognostic factor. Poulain et al. reported that 28% of COPD
patients showed DSpO2 X4% and the reproducibility of this
phenomenon was confirmed.16 They also showed that DSpO2
was not correlated with 6MWD, which is consistent with our
result. Mak et al.17 also reported that DSpO2 was not related
to 6MWD, the degree of perceived exertion, nor perceived
breathlessness. There have been a few reports concerning
the relationships between exercise-induced hypoxemia and
survival. Hiraga et al.18 showed that the cardiopulmonary
exercise test by treadmill was most closely associated with
survival. They found DPaO2/DVO2 more accurately and
quantitatively reflected the degree of the exercise-induced
hypoxemia than DSpO2. However, the measurement of
DPaO2/DVO2 was quite costly and might not be standard
clinical practice as they referred to in the discussion. Tojo
et al.19 recently reported that fall of PaO2 during cycle
ergometer was an independent predictor of mortality. They
speculated that repeated exercise-induced hypoxemia
induced vasoconstriction of the pulmonary artery, which
were responsible for the development of irreversible
pulmonary hypertension and resulted in poor prognosis. We
also speculate that cardiopulmonary dynamics associated
with cardiac output and pulmonary artery pressure cannot
compensate the oxygen desaturation during exercise in such
patients. This may be due to loss of functional reserve
capacity of the cardiopulmonary system, leading to poor
prognosis. In respect of the method of detecting exercise-
induced hypoxemia, the cardiopulmonary exercise test using
ARTICLE IN PRESS
N. Takigawa et al.566cycle ergometer was compared to the 6MW test.17 They
found that the 6MW test was more sensitive than the
cardiopulmonary exercise test for detecting oxygen desa-
turation. They also suggested that the 6MW test might have
the potential to become a diagnostic test as well, either to
measure dynamic hyperinflation or unmask exercise-induced
hypoxemia. Desaturation was also proven to be a prognostic
indicator for patients with interstitial pneumonia although
the definition was a fall in oxygen saturation to 88% or less
during 6MW test.20 In the present study, DSpO2 and 6MWD
were independently significant factors influencing survival.
These two parameters can be easily obtained because the
6MW test is carried out as clinical practice.
Our study has limitations. Firstly, we did not evaluate the
degree of dyspnea. We estimated it by the scale for the
patients with home oxygen therapy in Japan; however, it has
not been validated so far. Accordingly, we omitted the
evaluation of perceived breathlessness. Secondary, the cut-
off value of BMI (18 kg/m2), 6MWD (340m) and DSpO2 (6%)
was determined by the median value in this study popula-
tion. In the report of Celli et al.,4 the cut-off value of
BMI was 21 kg/m2; those of 6MWD were 350, 250, and 150m.
4% fall of DSpO2 was validated in a study of exercise-induced
hypoxemia in athletes and this 4% fall was defined as a fall of
2% to account for potential inaccuracy of oximetry
plus another fall of 2% to account for the right shift
of the hemoglobin saturation curve induced by exercise
metabolic acidosis.16,21 The median values of these
parameters should be validated in another population
and prospective design. Thirdly, we did not analyze the
patients who underwent LVRS in detail. The present
study could not show survival benefits of LVRS. Preliminary
data22 revealed that LVRS produced temporary palliation
without operative deaths, and there were lower rates of
upper lobe type emphysema, which was associated with
survival advantage from LVRS, compared to previous
reports.7,13 The detailed analysis regarding LVRS will be
published in the near future. Fourthly, we did not analyze
the data after PR in this study. Gerardi et al.15 identified the
12MWD after PR was the best predictor of mortality. The
mechanism for improving survival might be through im-
provement secured by the PR. The interaction of the effect
of the program with survival should be examined in the
future. Finally, only 12 (8%) women were included in this
study and to say something meaningful on gender and
mortality may be difficult.
In conclusion, both short distance and increase of DSpO2
showed significant independent poor prognosis. 6MWT was
very useful for predicting the prognosis in COPD patients. To
improve the outcome for the patients with poor prognosis,
new strategies including early intervention of PR for stage I
patients, drugs such as antioxidants, testosterone, and
erythropoietin, and intensive nutritional support should be
established.6Acknowledgments
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